ArticleObesity science & practice2026
Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies.
Article in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity increasingly influences treatment outcomes in urological malignancies (metastatic bladder cancer (BC), renal cell cancer (RCC), and prostate cancer (PC)). This study evaluated the impact of obesity on survival in patients with major metastatic urological cancers receiving systemic therapy. Materials and Methods: Patients with metastatic BC, RCC, and PC treated at a high-volume center from 2017 to 2025 were retrospectively analyzed. In total, 387 patients were included (BC: Results: Overall, 23.5% of the patients had obesity, with the highest prevalence in RCC (44.4%). In metastatic BC, obesity was not associated with differences in RMST at 24 months. In RCC, patients with obesity showed a numerical improvement in RMST and a significantly longer duration of systemic therapy. In contrast, patients with obesity with metastatic PC demonstrated significantly shorter RMST at 36 months than patients without obesity. Conclusion: The prognostic impact of obesity differs across metastatic urological malignancies. While the present findings support an obesity paradox in RCC, obesity was associated with worse survival in metastatic PC but showed no impact on survival in BC. These results highlight the need for tumor-specific biological interpretation of BMI-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.